PoliticsUnited States1 sourcesNeutral

Spinogenix Reports Early Improvements In Phase 2 Trial Of Tazbentetol In Patients With Schizophrenia At The Schizophrenia International Research Society (SIRS) 2026 Annual Congress

(MENAFN - PR Newswire) First-in-Class Synaptic Regenerative Therapy Demonstrates Favorable Safety Profile and Early Potential to Improve Symptoms of Schizophrenia LOS ANGELES, March 26, 2026 ...

Menafn

via Menafn

March 26, 2026 | 7:02 AM UTCUpdated 3h ago

Share Read original

Read the full article at Menafn →

Spinogenix Reports Early Improvements In Phase 2 Trial Of Tazbentetol In Patients With Schizophrenia At The Schizophrenia International Research Society (SIRS) 2026 Annual Congress

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Menafn

NewsDataUS

Comments

0 comments

Be respectful and constructive.

Loading comments...

Pokémon Champions Plans To Keep The Stadium Lights On For A Very Long Time

Politics

Chronic Law out of ICE custody after more than two months’ detention

Unknown-just now-1 sources

Politics

Labour Minister says payment under ROOFS programme will be made in phased batches

Unknown-1h ago-1 sources

Politics

Venezuela’s Maduro back in US court after capture

Unknown-2h ago-1 sources

Spinogenix Reports Early Improvements In Phase 2 Trial Of Tazbentetol In Patients With Schizophrenia At The Schizophrenia International Research Society (SIRS) 2026 Annual Congress

Source Verification

Comments

Pokémon Champions Plans To Keep The Stadium Lights On For A Very Long Time

HMP Global's 2026 SAWC Spring WHS Features First-To-Podium Research, NASA Keynote, Patients' Voice Forum

Related Articles

Chronic Law out of ICE custody after more than two months’ detention

Labour Minister says payment under ROOFS programme will be made in phased batches

Venezuela’s Maduro back in US court after capture